Drug Profile


Alternative Names: 240563; Bosatria; Mepolizamab; Nucala; SB-240563

Latest Information Update: 14 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; McMaster University
  • Class Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypereosinophilic syndrome; Churg-Strauss syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma
  • Preregistration Churg-Strauss syndrome
  • Phase III Chronic obstructive pulmonary disease; Hypereosinophilic syndrome; Nasal polyps
  • Phase II Atopic dermatitis
  • No development reported Eosinophilic oesophagitis

Most Recent Events

  • 12 Sep 2017 GlaxoSmithKline plans to file an regulatory application for Chronic obstructive pulmonary disease in 2017
  • 12 Sep 2017 Safety and efficacy data from the two phase III METREX and METREO trials in Chronic obstructive pulmonary disease released by GlaxoSmithKline
  • 11 Aug 2017 GlaxoSmithKline completes a phase III trial in pharmacokinetics trial for Asthma (In volunteers) in USA, Germany and United Kingdom (SC) (NCT03014674)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top